- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03570411
Evaluating the Clinical Utility of the T-SPOT.CMV Assay for the Prediction of CMV Reactivation Among Pediatric Patients Undergoing Hematopoietic Cell Transplant
The ability to distinguish allogeneic hematopoietic cell transplantation (allo-HCT) recipients at risk for cytomegalovirus (CMV) reactivation from those who are not is central for optimal CMV management strategies. Measuring this cell mediated immunity has been proposed as a potent tool to predict those patients at highest risk of CMV reactivation and disease. This study will evaluate the ability of the T-SPOT.CMV test to predict Cytomegalovirus (CMV) reactivation in allogeneic hematopoietic cell transplantation (allo-HCT) pediatric recipients.
Primary Objectives:
To evaluate feasibility of T-SPOT.CMV spot count test in allo-HCT pediatric recipients.
To evaluate association of T-SPOT.CMV spot count in the first sample collected after patient has engrafted with subsequent CMV reactivation in allo-HCT pediatric recipients.
Secondary Objectives:
To evaluate the correlation between T-SPOT.CMV spot count in donors with subsequent recipient CMV spot count.
To explore the relationship between recipient T-SPOT.CMV spot counts and subsequent CMV infection related morbidity and treatment outcomes among pediatric all-HCT recipients.
Study Overview
Detailed Description
T-SPOT response will be measured using the results from the T-SPOT.CMV blood test in both HCT recipients and HCT donors.
A blood sample for the T-SPOT.CMV blood test will be collected from the HCT donor prior to transplant.
Blood specimens will be collected for the T-SPOT.CMV blood test from HCT recipients over the course of 6 months, starting weekly at Day +1, biweekly starting at Day +45, and monthly starting at day +120.
HCT recipient participant demographic and clinical characteristics will be collected at enrollment. Additional clinical information will be abstracted from the HCT recipient participants medical record during the study follow-up period. This will include information related to transplant history and outcome, infections, antimicrobial exposure, chemotherapy, and laboratory values related to infectious diseases and immunosuppression.
The feasibility of the T-SPOT.CMV spot count test will be evaluated once the first 30 participants enrolled on study reach day +90. If 75% of patients have at least 1 evaluable samples after engraftment (> 75,000 per microtiter wells), we will proceed with enrollment. If more >25% of patients have all their samples deemed not evaluable due to insufficient mononuclear cell count (<75,000 per microtiter wells) the study will be stopped and concluded as not feasible.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Tennessee
-
Memphis, Tennessee, United States, 38105
- St. Jude Children's Research Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
HCT Recipient Inclusion Criteria
- Less than 18 years old at the time of study enrollment
- Scheduled to receive allogeneic HCT at St Jude Children's Research Hospital
- HCT recipient has a documented seropositive CMV result prior to enrollment OR The HCT recipient is seronegative, but the HCT donor has a seropositive CMV result as documented in the recipient's medical record.
HCT Recipient Exclusion Criteria
- Any condition or therapy that would, in the opinion of the investigator, place the subject at an unacceptable risk of injury, render the subject unable to meet the requirements of the study, or impact the outcome of the study.
- Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.
HCT Donor Inclusion Criteria
• Approved allogeneic HCT donor for a HCT recipient enrolled on the SPOTCMV protocol
HCT Donor Exclusion Criteria
• Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
HCT Recipient
All participants who meet eligibility criteria and consent to enrollment on study. Blood specimens will be collected for the T-SPOT.CMV blood test from HCT recipients over the course of 6 months, starting weekly at Day +1, biweekly starting at Day +45, and monthly starting at day +120. The amount of blood collected at each visit will be based on age. |
The T-SPOT.CMV test (Oxford Diagnostic Laboratories) measures the strength of T cell responses to CMV specific antigens.
Using whole blood samples obtained through a standard blood collection tube, white blood cells (WBC's) are separated and purified.
The cells are quantified and placed into specially designed plates where they are challenged with antigens specific to the disease under study.
Disease-specific cells responding to these antigens will release immune messenger molecules, called cytokines.
We then use chemistry to allow us to visualize those WBCs releasing cytokines (and hence those which react to the antigen), resulting in a spot on the bottom of the plate, corresponding to the footprint of an individual reacting WBC.
Finally, we use an automated image analysis system to identify and count each of these spots to give a quantitative readout.
That quantitative readout gives us the frequency of responsive disease-specific cells (Oxford Immunotec, 2017).
|
HCT Donor
Approved allogeneic HCT donor for a HCT recipient enrolled on the SPOTCMV protocol A blood sample for the T-SPOT.CMV blood test will be collected from the HCT donor prior to transplant |
The T-SPOT.CMV test (Oxford Diagnostic Laboratories) measures the strength of T cell responses to CMV specific antigens.
Using whole blood samples obtained through a standard blood collection tube, white blood cells (WBC's) are separated and purified.
The cells are quantified and placed into specially designed plates where they are challenged with antigens specific to the disease under study.
Disease-specific cells responding to these antigens will release immune messenger molecules, called cytokines.
We then use chemistry to allow us to visualize those WBCs releasing cytokines (and hence those which react to the antigen), resulting in a spot on the bottom of the plate, corresponding to the footprint of an individual reacting WBC.
Finally, we use an automated image analysis system to identify and count each of these spots to give a quantitative readout.
That quantitative readout gives us the frequency of responsive disease-specific cells (Oxford Immunotec, 2017).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of the first 30 participants with at least one evaluable sample
Time Frame: Day +90 after transplant
|
Percentage of the first 30 participants enrolled on study reach day +90 with at least one evaluable sample will be reported.
|
Day +90 after transplant
|
Odds ratio of subsequent reactivation
Time Frame: Up to 180 days after enrollment.
|
We define the primary endpoint to the T-SPOT CMV count in the first sample collected after patient has engrafted, which is the time point when one establishes his/her post-transplant immunity.
If the count in this sample is less than or equal to 100, the participant will be noted as "low response", while an individual with a spot count greater than 100 will be noted as "high response".
Odds ratio of having subsequent CMV reactivation between "low response" and "high response" groups will be estimated.
|
Up to 180 days after enrollment.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation coefficient of T-SPOT.CMV spot count in donors with subsequent recipient CMV spot count
Time Frame: Up to 180 days after enrollment.
|
The correlation coefficient between T-SPOT.CMV spot count in donors (one-time measure) and maximal recipient's CMV spot count will be calculated with Pearson's or Spearman's correlation coefficient.
|
Up to 180 days after enrollment.
|
Odds ratio of morbidity
Time Frame: Up to 180 days after enrollment.
|
The odds ratio with 95% CI of morbidity will be reported from multiple logistic regression.
|
Up to 180 days after enrollment.
|
Odds ratio of treatment outcomes
Time Frame: Up to 180 days after enrollment.
|
The odds ratio with 95% CI of treatment outcomes will be reported from multiple logistic regression.
|
Up to 180 days after enrollment.
|
Hazard ratio of morbidity
Time Frame: Up to 180 days after enrollment.
|
The hazard ratio with 95% CI of morbidity will be reported from Cox regression model.
|
Up to 180 days after enrollment.
|
Hazard ratio of treatment outcomes
Time Frame: Up to 180 days after enrollment.
|
The hazard ratio with 95% CI of treatment outcomes will be reported from Cox regression model.
|
Up to 180 days after enrollment.
|
Collaborators and Investigators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- SPOTCMV
- NCI-2018-01349 (Registry Identifier: NCI Clinical Trial Registration Program)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on CMV
-
St George's, University of LondonSt George's University Hospitals NHS Foundation TrustActive, not recruitingCMV | Congenital Cmv | Maternal Infections Affecting Fetus or Newborn | Shedding VirusUnited Kingdom
-
Grupo Espanol de trasplantes hematopoyeticos y...Not yet recruiting
-
QIAGEN Gaithersburg, IncTerminated
-
Medical University of South CarolinaTakedaRecruitingCMV | Transplant ComplicationUnited States
-
Meridian Bioscience, Inc.Completed
-
University Hospital, LimogesUniversity Hospital, LilleCompleted
-
Virginia Commonwealth UniversityMerck Sharp & Dohme LLCRecruitingCMV | Kidney Transplant; ComplicationsUnited States
-
Fundación para la Investigación del Hospital Clínico...Completed
-
Imperial College LondonWithdrawnAllogeneic Stem Cell Transplantation | CMV Reactivation | Autologous CMV Specific CD8+ T CellsUnited Kingdom
Clinical Trials on T-SPOT®.CMV Test
-
M.D. Anderson Cancer CenterCompleted
-
University Health Network, TorontoOxford ImmunotecCompleted
-
Henry M. Jackson Foundation for the Advancement...Infectious Diseases Clinical Research ProgramCompletedLatent Tuberculosis InfectionUnited States
-
University of Lausanne HospitalsCompleted
-
Chinese PLA General HospitalRecruiting
-
Xiao-Jun HuangRecruitingAllogeneic Hematopoietic Stem Cell Transplantation | CMV InfectionChina
-
University of Erlangen-Nürnberg Medical SchoolGerman Research Foundation; Charite University, Berlin, Germany; Ludwig-Maximilians... and other collaboratorsCompletedPatients Undergoing Allogeneic Stem Cell TransplantationGermany
-
Hebei Yanda Ludaopei HospitalChina Immunotech (Beijing) Biotechnology Co., Ltd.CompletedCMV Infection or Reactivation After Allogenic HSCTChina
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...CompletedCytomegalovirus Infection | Adenovirus InfectionUnited States
-
Rennes University HospitalCompleted